Find Capmatinib Hydrochloride manufacturers, exporters & distributors on PharmaCompass

Capmatinib Hydrochloride

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

3 API Suppliers, 1 USDMF, 2 NDC API, 2 Listed Suppliers

3 API Suppliers
1 USDMF
2 NDC API
2 Listed Suppliers

DEVELOPMENTS

7 Drugs in Development

7 Drugs in Development

FINISHED DOSAGE FORMULATIONS

2 FDF Dossiers, 2 FDA Orange Book

2 FDF Dossiers
2 FDA Orange Book

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 14 NEWS #PharmaBuzz

media
1 DATA COMPILATION #PharmaFlow
14 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions

globalSalesInformation
1 US Medicaid Prescriptions

PATENTS & EXCLUSIVITIES

12 US Patents, 4 US Exclusivities

patents
12 US Patents
4 US Exclusivities

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

7DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

70,283,872

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1865733-40-9, Nvp-inc280-aaa, Capmatinib hydrochloride [usan], C2a374o70x, Capmatinib (dihydrochloride hydrate), Tabrecta

Molecular Formula

C₂₃H₂₁Cl₂FN₆O₂

Molecular Weight

503.4 g/mol

InChI Key

COWBUPJEEDYWKD-UHFFFAOYSA-N

FDA UNII

C2A374O70X

Capmatinib Hydrochloride is the hydrochloride salt form of capmatinib, an orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.

1 2D Structure

Capmatinib Hydrochloride

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide;hydrate;dihydrochloride

2.1.2 InChI

InChI=1S/C23H17FN6O.2ClH.H2O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20;;;/h2-9,11-13H,10H2,1H3,(H,25,31);2*1H;1H2

2.1.3 InChI Key

COWBUPJEEDYWKD-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F.O.Cl.Cl

2.2 Other Identifiers

2.2.1 UNII

C2A374O70X

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 2-fluoro-4-(7-((quinolin-6-yl)methyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzoic Acid

2. 2-fluoro-4-(7-((quinolin-6-yl)methyl)imidazo(1,2-b)-(1,2,4)triazin-2-yl)benzamide

3. 2-fluoro-n-methyl-4-(7-((quinolin-6-yl)methyl)imidazo(1,2- B)(1,2,4)triazin-2-yl)benzamide Dihydrochloride Monohydrate

4. 2-fluoro-n-methyl-4-(7-(quinolin-6-yl-methyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide

5. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide

6. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide Dihydrochloride

7. Capmatinib

8. Capmatinib Dihydrochloride

9. Capmatinib Dihydrochloride Monohydrate

10. Capmatinib Hydrochloride Anhydrous

11. Capmatinib Metabolite M13

12. Capmatinib Metabolite M18

13. Cmc-583

14. Cmc583

15. Cnj-294

16. Cnj294

17. Inc-280

18. Inc280

19. Incb-28060

20. Incb-28060 Free Base

21. Incb28060

22. Nvp-inc280

23. Nvp-inc280-nx

24. Tabrecta

2.3.2 Depositor-Supplied Synonyms

1. 1865733-40-9

2. Nvp-inc280-aaa

3. Capmatinib Hydrochloride [usan]

4. C2a374o70x

5. Capmatinib (dihydrochloride Hydrate)

6. Tabrecta

7. Capmatinib Dihydrochloride Monohydrate

8. Capmatinib Hydrochloride (usan)

9. Capmatinib Hydrochloride Hydrate (jan)

10. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide Dihydrochloride Hydrate

11. Capmatinib Hydrochloride Hydrate [jan]

12. Tabrecta (tn)

13. Capmatinib 2hcl.h2o

14. Capmatinib 2hcl Hydrate

15. Inc-280 Hydrochloride

16. Incb28060 Hydrochloride

17. Unii-c2a374o70x

18. Capmatinib Hydrochloride Hydrate

19. Chembl3989937

20. Dtxsid401027869

21. Hy-13404c

22. Capmatinib Hydrochloride [who-dd]

23. Capmatinib Hydrochloride Monohydrate

24. Cs-0198834

25. Capmatinib Hydrochloride [orange Book]

26. D10891

27. Q27895918

28. 2-fluoro-n-methyl-4-(7-((quinolin-6-yl)methyl)imidazo(1,2- B)(1,2,4)triazin-2-yl)benzamide Dihydrochloride Monohydrate

29. Benzamide, 2-fluoro-n-methyl-4-(7-(6-quinolinylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)-, Hydrochloride, Hydrate (1:2:1)

2.4 Create Date

2016-11-15

3 Chemical and Physical Properties

Molecular Formula	C₂₃H₂₁Cl₂FN₆O₂
Molecular Weight	503.4 g/mol
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	4
Exact Mass	502.1087075 g/mol
Monoisotopic Mass	502.1087075 g/mol
Topological Polar Surface Area	86.1 Å²
Heavy Atom Count	34
Formal Charge	0
Complexity	637
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	4

4 Drug and Medication Information

4.1 Drug Indication

Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

5 Pharmacology and Biochemistry

5.1 ATC Code

L01EX17

API SUPPLIERS